Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Rabbit Monoclonal Antibodies Now Available for Use in Cancer-Related Research

By BiotechDaily International staff writers
Posted on 08 Aug 2011
Cancer researchers now have access to 23 novel, cancer-related rabbit monoclonal antibodies that have been released to the commercial market.

The antibodies are the fruit of cooperation between the [US] National Cancer Institute (Bethesda, MD, USA) and the biotechnology company Epitomics, Inc. (Burlingame, CA, USA). Epitomics has developed a unique and proprietary method for making monoclonal antibodies from rabbits rather than the conventional method of starting with mice.

The basic principal for making the antibody is the same as for mouse monoclonal antibodies. Proprietary rabbit fusion-partner cells fuse to rabbit B-cells to create rabbit hybridoma cells. Hybridomas are then screened to select for clones with specific and sensitive antigen recognition, and the antibodies are characterized using a variety of methods. The rabbit immune system generates antibody diversity and optimizes affinity by mechanisms that are more efficient than those of mice and other rodents. This increases the possibility of obtaining a functional antibody that will work in a variety of applications.

This technology - combined with the expertise of researchers at the National Cancer Institute – has produced a line of 23 rabbit monoclonal antibodies that should be of use to cancer investigators. The antibodies are available for purchase in the United States directly through Epitomics and around the world through Epitomics’ international distributors. The collaborators plan to develop another 20 antibodies for commercial release over the next two years.

“We are very excited to see the progress we have made in developing several key antibodies with National Cancer Institute investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies,” said Dr. Guo-Liang Yu, CEO of Epitomics, Inc.

Related Links:

National Cancer Institute
Epitomics, Inc.



Channels

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.